Early Phase 1 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People with mild to severe plaque psoriasis, where at least 2% of the body's skin surface is affected, and where a doctor has confirmed the severity using standard psoriasis scoring tools
Who may not be able to join:
- People currently taking medication that changes the normal balance of certain minerals (ions) in the blood
- People who have taken calcium supplements (not counting standard multivitamins) in the month before the study start date
- People with an unstable or poorly controlled illness, including but not limited to heart or blood vessel conditions, breathing problems, liver, kidney, or digestive conditions, hormonal disorders, blood disorders, neurological conditions, or mental health conditions
- People whose blood test results at screening are considered abnormal in a way that, in the doctor's opinion, could affect their safety or the reliability of the study data
- People who have used certain systemic (whole-body) non-biologic treatments for psoriasis — such as cyclosporine, methotrexate, corticosteroids, oral retinoids, or similar medicines — within 28 days before the study start date
- People who have had phototherapy (such as UVB light therapy, PUVA, excimer laser, tanning beds, or therapeutic sunbathing) within 28 days before the study start date
- People who have used certain topical (skin-applied) treatments — including most corticosteroid creams, calcipotriene, vitamin D-based creams, retinoids, coal tar shampoos, or products with more than 3% salicylic acid — within 14 days before the study start date (confirm with trial site for the full list of permitted and excluded products)
- People who have used biologic medicines within 8 weeks, or within three half-lives of the medicine (whichever is the longer period), before the study start date
- People with a history of kidney (renal) problems or reduced kidney function
- People with a history of kidney stones
- People with a history of parathyroid gland abnormalities
- People who have osteoporosis (weakened or brittle bones)
- People with a history of severe arthritis
- People who regularly use a tanning bed, UV device, or spend excessive time in direct sunlight
- People who are unable to understand or complete the informed consent process
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeffrey B Travers, MD, PhD, Wright State University
Phone: 937-245-7500
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in Psoriasis Area and Severity Score (PASI) from baseline; Improvement in Investigator Grade Assessment (IGA) from baseline; Improvement in Body Surface Area (BSA) from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.